<DOC>
	<DOCNO>NCT01215773</DOCNO>
	<brief_summary>The main objective multiple dose study investigate safety , tolerability pharmacokinetics BI 671800 HEA healthy male female volunteer follow multiple oral administration BI 671800</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability BI 671800 HEA Given Over 7 Days . A Randomised , Double Blind , Placebo Controlled Within Dose Groups Phase I Study Healthy Male Female Volunteers .</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age 21 50 year ( incl . ) 3 . Body Mass Index ( BMI ) 18.5 29.9 kg/m2 ( incl . ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History relevant allergy hypersensitivity ( include allergy drug excipients ) 8 . Intake drug long half life ( &gt; 24 h ) within one month le 10 halflives respective drug prior first study drug administration 9 . Participation another trial investigational drug within 2 month prior administration trial 10 . Smoker ( 10 cigarette 3 cigar 3 pipe daily ) 11 . Alcohol abuse ( average consumption 20 g/day female 30 g/day male ) positive alcohol test 12 . Drug abuse 13 . Blood donation ( 100 mL within four week prior day 1 visit 2 ) 14 . Any laboratory value outside reference range clinical relevance , especially repeat Alanine transaminase ( ALT ) , Aspartate transaminase ( AST ) , Gammaglutamyltransferase ( GGT ) , Alkaline phosphatase ( ALP ) total bilirubin upper limit normal ( ULN ) screen resolve dosing . 15 . Inability comply dietary regimen trial site 16 . Use drug might reasonably influence result trial prolong QT/QTc interval within 10 day prior administration trial , CYP2C8 substrates amiodarone , amodiaquine , paclitaxel , rosiglitazone , pioglitazone repaglinide CYP2C9 warfarin , tolbutamide , phenytoin , losartan , acenocoumarol within 1 month six half life ( whichever great ) . 17 . Repeated demonstration QTc interval &gt; 450 m , PR interval &gt; 230 m QRS interval &gt; 120 m ; history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome ) For female subject childbearing potential : 18 . Positive pregnancy test , pregnancy plan become pregnant study within 2 month study completion 19 . No adequate contraception study include three month first dose 2 month study completion , e.g . follow : implant , injectables , combine hormonal contraceptive , intrauterine device , surgical sterilisation ( include hysterectomy ) . In addition , also barrier method ( e.g . condom ) require , female surgically sterilise . 20 . Lactation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>